Analysis on the efficacy of non-laser post-LASIK keratectasia treatment by implantation of intracorneal ring segments using a new device

Session Details

Session Title: Cornea

First Author: S. Izmaylova Russia

Co. Authors :    B. Malyugin   D. Merzlov   E. Poruchikova              

Abstract Details:



Purpose:

To evaluate the efficacy of non-laser post-LASIK keratectasia treatment by implantation of intracorneal ring segments (ICRS) using a new device.

Setting:

Fyodorov Eye Microsurgery Complex, Corneal Department, Russia, Moscow, Beskudnikovsky Boulevard 59A, 127486

Methods:

The investigation enrolled 18 patients (18 eyes) with secondary post-LASIK keratectasia. Standard pre- and postoperative examination included: UCVA, BCVA, Keratotopografy maps, ultrasound pachymetry and confocal microscopy. We implanted one or two ICRS depending on keratectasia type – symmetric or asymmetric. ICRS made of PMMA, 150 to 350 m thickness, 160 length were implanted at the depth of 80 of corneal thickness. We used a unique technique of ICRS implantation with the help of calibrated vacuum ring (CVR). It helps to fix the eye properly, mark 5-7 mm corneal zone and incision projection, make corneal tunnel more easily thanks to increase in rigidity of dystrophic flexible cornea. It reduced eye-ball traumatism and decreased risk of perforation. Follow-up period was 3-48 months.

Results:

Post-op results are described as stable throughout follow-up and average indices showed: UCVA 0,440,14; BCVA 0,70,25; spherical eguivalent -1,750,5 D, cylindrical eguivalent –0,750,8D; refractive power in the area of maximal ectasia 41,52,23 D, central corneal thickness 44011m. Confocal microscopy revealed reduction of quantity and intensity of supraendothelial folds and pronounced fibroplastic reaction in the area of implanted ICRS. There were no major complications during or after surgery.

Conclusions:

Non-laser ICRS implantation using CVR is a safe and effective treatment for post-LASIK keratectasia. All parameters showed improvement at 48 months follow-up. FINANCIAL DISCLOSURE:None